The grades of four Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Keryx Biopharmaceuticals (NASDAQ:KERX) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Keryx Biopharmaceuticals focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. The stock price has risen 120.9% over the past month, better than the 2.3% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of KERX stock.
The rating of Astex Pharmaceuticals (NASDAQ:ASTX) moves up this week, rising from a C to a B. Astex Pharmaceuticals engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. Wall Street seems to agree with the upgrade and has propelled the stock up 10.9% over the past month. For more information, get Portfolio Grader’s complete analysis of ASTX stock.
3SBio (NASDAQ:SSRX) earns a B this week, jumping up from last week’s grade of C. 3SBio is a biotechnology company that engages in the research and development, manufacture, and distribution of pharmaceutical products in the Peoples Republic of China. For more information, get Portfolio Grader’s complete analysis of SSRX stock.
PDL BioPharma (NASDAQ:PDLI) shows solid improvement this week. The company’s rating rises from a C to a B. PDL discovers, develops, and markets therapies for serious or life-threatening illnesses, commercially focused on the acute care, hospital setting. The stock currently has a trailing PE Ratio of 4.90. For more information, get Portfolio Grader’s complete analysis of PDLI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.